Dr. Flores, received his medical degree from the University Catolica Santiago de Guayaquil in Ecuador. He completed his residency in pediatrics at the University of Miami, Jackson Memorial Hospital in Miami, Florida. Dr. Flores then completed his fellowship in pediatric nephrology at Harvard University, Boston Children’s Hospital in Boston, Massachusetts. In 1998, he started the Pediatric Nephrology Program at Tampa Children’s Hospital, in Tampa Florida and 2002, he joined the University of South Florida Morsani College of Medicine and served as an attending physician in Pediatric Nephrology at All Children’s Hospital in St. Petersburg, Florida. Over the last 14 years at All Children’s Hospital, Dr. Flores focused his clinical interest and work in the use of continuous renal replacement therapy in pediatric acute kidney injury; and in 2008 he became the director of the CRRT Program at this institution. In 2011, Dr. Flores developed the Molecular Adsorbent Recirculating System (MARS) Program at All Children’s Hospital, which at that time became the second pediatric program in the US and the only program in Florida that provided supportive therapy to children with drug overdose, poisoning and acute liver failure.
In June of 2016, Dr. Flores joined the Division of Pediatric Nephrology and Hypertension as the medical director of clinical services and the MARS Program at Cincinnati Children’s Hospital Medical Center.
Dr. Flores’ areas of clinical interest include acute kidney injury, the use of continuous renal replacement therapy and the use of MARS in pediatric patients.
MD: Universidad Catolica Santiago de Guayaquil, Guayaquil, Ecuador.
Residency: University of Miami Jackson Memorial Medical Center, Miami, Florida.
Fellowship: Children’s Hospital, Harvard Medical School, Boston, Massachusetts.
Certification: Pediatric Nephrology, 1999.
Pediatric AKI; use of continuous renal replacement therapy (CRRT) in pediatric patients; use of molecular adsorbent recirculating system (MARS) in pediatric patients
Nephrology and Hypertension, Kidney Transplant
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Carfilzomib-based antibody mediated rejection therapy in pediatric kidney transplant recipients. Pediatric Transplantation. 2023; 27:e14534.
Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE. Lupus Science and Medicine. 2023; 10.
International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Arthritis and Rheumatology. 2022; 74:263-273.
Primary hyperoxaluria diagnosed after kidney transplant: A review of the literature and case report of aggressive renal replacement therapy and lumasiran to prevent allograft loss. American Journal of Transplantation. 2021; 21:4061-4067.
Glomerular Hyperfiltration Is Associated with Liver Disease Severity in Children with Nonalcoholic Fatty Liver Disease. The Journal of Pediatrics. 2020; 222:127-133.
Evaluation of a change in cytomegalovirus prevention strategy following pediatric solid organ transplantation. Transplant Infectious Disease. 2020; 22:e13232.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey